Adamas Pharmaceuticals Presents Positive Phase 2/3 Results for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia (LID) in Parkinson's Disease
6/18/2013 10:04:04 AM
More...
|
Adamas Pharmaceuticals to Report Positive Phase 2/3 Results For ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease
6/10/2013 10:28:41 AM
More...
|
Adamas Pharmaceuticals Announces Issuance of First U.S. Patent for Nurelin™ (Amantadine HCl Extended Release) Program
4/22/2013 11:12:57 AM
More...
|
Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data From Its Nurelin™ Program at American Academy of Neurology Conference
3/20/2013 9:21:41 AM
More...
|
Forest Laboratories, Inc. (FRX) and Adamas Pharmaceuticals Form Alliance for Up to $160 Million
11/14/2012 6:59:28 AM
More...
|
Adamas Pharmaceuticals Presents Update On Nurelin(TM) Program at Cambridge Healthtech Institute's Parkinson's Conference
6/4/2012 12:26:07 PM
More...
|
Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinson's Disease
9/28/2011 5:57:32 AM
More...
|
Adamas Pharmaceuticals' Triple Combination Antiviral Drug (TCAD) Therapy is Well Tolerated in a Pilot Study of Immunocompromised Patients With Influenza A
4/28/2010 10:58:49 AM
More...
|
Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
2/22/2010 9:01:28 AM
More...
|
Adamas Pharmaceuticals Selects Veeva Systems, Inc.'s CRM to Support New Product Commercialization and Anticipated Growth
10/28/2009 10:15:22 AM
More...
|
|